Filing Flows

Filing Flows › PTC Therapeutics (PTCT) › Next earnings date

PTC Therapeutics (PTCT) earnings: missed the estimate

PTC Therapeutics (PTCT) reported on Oct 29, 2026 and missed the EPS estimate: −$0.39 against $0.27 (-243.9%). Revenue was $358M for Q3 2026, +70% year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result−243.9% vs estimate
Beat rate60%

The last report

PTC Therapeutics reported revenue of $358M for the third quarter 2026 (+70% Y/Y), net loss $51.7M: Net product revenue $276M, Royalty revenue $81.7M, Collaboration and license revenue $229K. How it makes money → · Every quarter →

PTC Therapeutics: EPS against the estimate, last 5 reportsPTC Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$1.11$0.19Nov 25−$0.41−$1.80Feb 26−$0.44−$0.03May 26$0.34$0.92Jul 26$0.27−$0.39Oct 26
Latest (Oct 26): Estimate $0.27, Reported −$0.39.

PTC Therapeutics' latest quarter

PTC Therapeutics, Q3 2026: revenue $358M (+70% year over year), operating margin 7.0%, net loss $51.7M, operating cash flow −$25.3M. The chart follows the revenue to costs, profit and cash.

Questions

Did PTC Therapeutics beat earnings?

PTC Therapeutics (PTCT) reported on Oct 29, 2026 and missed the EPS estimate: −$0.39 against $0.27 (-243.9%).

When does PTCT report earnings?

The next date is not set yet.

Does PTC Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.